Jetzt 20% Rabatt auf alle English Books. Jetzt in über 4 Millionen Büchern stöbern und profitieren!
Willkommen, schön sind Sie da!
Logo Ex Libris

Risk-sharing in the Pharmaceutical Industry

  • E-Book (pdf)
  • 297 Seiten
(0) Erste Bewertung abgeben
Bewertungen
(0)
(0)
(0)
(0)
(0)
Alle Bewertungen ansehen
The productivity in pharmaceutical research and development faces intense pres­ sure. R&D expenditures of the major US and Europe... Weiterlesen
CHF 165.90
Download steht sofort bereit
Informationen zu E-Books
E-Books eignen sich auch für mobile Geräte (sehen Sie dazu die Anleitungen).
E-Books von Ex Libris sind mit Adobe DRM kopiergeschützt: Erfahren Sie mehr.
Weitere Informationen finden Sie hier.
Bestellung & Lieferung in eine Filiale möglich

Beschreibung

The productivity in pharmaceutical research and development faces intense pres­ sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re­ cord level of close to US$ 1 billion today. As a result, any failure of a new sub­ stance in the R&D process can lead to considerable losses, and the risks of introduc­ ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year.



Inhalt

Key Issues in Managing Pharmaceutical Innovation.- Risk-sharing as New Paradigm in Pharma R&D Collaborations.- Case Studies on Risk-sharing in Pharma R&D Collaborations.- Characteristics of Risk-sharing in Pharma R&D Collaborations.- Theoretical Basis for Risk-sharing in Pharma R&D Collaborations.- Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations.- Conclusion.

Produktinformationen

Titel: Risk-sharing in the Pharmaceutical Industry
Untertitel: The Case of Out-licensing
Autor:
EAN: 9783790816686
ISBN: 978-3-7908-1668-6
Format: E-Book (pdf)
Hersteller: Physica-Verlag HD
Herausgeber: Physica-Verlag
Genre: Wirtschaft
Veröffentlichung: 25.02.2006
Digitaler Kopierschutz: Wasserzeichen
Dateigrösse: 29.39 MB
Anzahl Seiten: 297
Jahr: 2006

Weitere Bände aus der Buchreihe "Contributions to Management Science"